Big Flats, NY, March 1, 2017 – X-GEN Pharmaceuticals announced today it will begin marketing and distributing Piperacillin and Tazobactam for Injection. X-GEN’s Piperacillin and Tazobactam for Injection is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for the treatment of various bacterial infections.

The medical community has been plagued by shortages and inconsistencies in the supply of Piperacillin and Tazobactam for Injection for several years. In an effort to close the gap, X-GEN has been working closely with its supply chain and the Food and Drug Administration to bring this product to market and alleviate supply shortages and uncertainty. X-GEN’s Chief Operating Officer, Rob Liles, stated that “X-GEN continues to emphasize a growth strategy through new product introductions and business alliances.” He further stated “these efforts combined with X-GEN’s ability to quickly react to market conditions created the opportunity to stabilize the availability of this popular treatment option.”